'OLAP' (OLAparib regulatory Post-marketing surveillance) - OLAP

Study identifier:D0817R00010

ClinicalTrials.gov identifier:NCT04553926

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Lynparza tablet (olaparib) Regulatory Post-Marketing Surveillance

Medical condition

ovarian cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

650

Study type

Observational

Age

19 Years - 150 Years

Date

Study Start Date: 01 Feb 2021
Estimated Primary Completion Date: 30 Jun 2025
Estimated Study Completion Date: 30 Jun 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria